NCT05239260

Brief Summary

Correlation between CMR T1-times, liver T1-times, fibroscan and fluid status to identify the correlation and pathogenesis of liver disease in patients with heart disease.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
150

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Feb 2022

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2022

Completed
4 days until next milestone

First Submitted

Initial submission to the registry

February 5, 2022

Completed
9 days until next milestone

First Posted

Study publicly available on registry

February 14, 2022

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2022

Completed
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2023

Completed
Last Updated

February 14, 2022

Status Verified

February 1, 2022

Enrollment Period

3 months

First QC Date

February 5, 2022

Last Update Submit

February 5, 2022

Conditions

NAFLD/MAFLDLiver FibrosisCMR

Keywords

NAFLDCMR

Outcome Measures

Primary Outcomes (1)

  • Impact of fluid status on liver elastography and T1-times

    5 months

Interventions

CMRDIAGNOSTIC_TEST

CMR

Also known as: Fibroscan, Body composition monitor

Eligibility Criteria

Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All-comer cohort referred for Cardiovascular Magnetic Resonance Imaging

You may qualify if:

  • Referred for Cardiovascular Magnetic Resonance Imaging

You may not qualify if:

  • Non-compatible Devices

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Medical University Vienna

Vienna, 1090, Austria

RECRUITING

MeSH Terms

Conditions

Non-alcoholic Fatty Liver DiseaseLiver Cirrhosis

Condition Hierarchy (Ancestors)

Fatty LiverLiver DiseasesDigestive System DiseasesFibrosisPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Andreas Kammerlander

    Medical University of Vienna

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Katharina Mascherbauer

CONTACT

0043 1 40400 48590katharina.mascherbauer@meduniwien.ac.at

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD Phd

Study Record Dates

First Submitted

February 5, 2022

First Posted

February 14, 2022

Study Start

February 1, 2022

Primary Completion

May 1, 2022

Study Completion

January 1, 2023

Last Updated

February 14, 2022

Record last verified: 2022-02

Locations

AU(1)